UNIVERSAL HEALTH SERVICES INC quarterly report, Q1 FY2024

Universal Health Services, Inc. — Q1 2024 Form 10-Q Summary

Business context and reporting period

Universal Health Services, Inc. and subsidiaries filed an unaudited Form 10-Q for the three months ended March 31, 2024, compared with the three months ended March 31, 2023. UHS operates acute care and behavioral health facilities in the United States, the United Kingdom, Puerto Rico and Washington, D.C. As of March 31, 2024, it owned or operated 360 inpatient facilities and 47 outpatient and other facilities.

Reportable segments: acute care hospital services and behavioral health care services.
Q1 revenue mix: approximately 57% acute care, outpatient facilities and commercial health insurer revenue; 43% behavioral health care and commercial health insurer revenue.
U.K. behavioral health revenue was approximately $208 million, compared with $168 million in Q1 2023.

Financial performance and key metrics

Metric	Q1 2024	Q1 2023	Change
Net revenues	$3.844 billion	$3.468 billion	+10.8%
Income from operations	$389 million	$279 million	+39.5%
Operating margin	10.1%	8.0%	+210 basis points
Income before income taxes	$336 million	$214 million	+57%
Net income attributable to UHS	$262 million	$163 million	+61%
Diluted EPS	$3.82	$2.28	+$1.54
Net cash provided by operating activities	$396 million	$291 million	+$106 million
Capital expenditures	$209 million	$169 million	+$40 million

Consolidated net margin was 6.9%, compared with 4.7% in the prior-year quarter.
Salaries, wages and benefits were $1.843 billion, or 47.9% of revenue, versus 50.6% in Q1 2023. Premium-pay labor expense declined by approximately $18 million in the acute care same-facility operations.
Interest expense increased to $53 million from $51 million. The average effective borrowing rate was approximately 5.1%, versus 4.7% in Q1 2023.
The effective tax rate declined to 20.9% from 24.2%, primarily due to a lower tax benefit from employee share-based payments and increased income attributable to noncontrolling interests.

Segment and operating trends

Acute care: Same-facility revenue increased 9.6% to $2.107 billion, while same-facility income before taxes increased 45% to $207 million. Admissions increased 5.7%, patient days increased 4.4%, and occupancy of available beds rose to 70.4% from 68.7%.
Behavioral health: Same-facility revenue increased 10.4% to $1.616 billion, while same-facility income before taxes increased 20% to $319 million. Admissions declined 0.6%, but patient days increased 2.2% and occupancy of available beds rose to 73.0% from 72.3%.
Acute care performance benefited from higher volumes, improved labor productivity and approximately $38 million of net reimbursements under Nevada’s state-directed Medicaid payment program.
Behavioral health revenue growth benefited from higher revenue per adjusted admission and increased U.K. revenue; staffing and other operating costs also increased.
Provider tax programs generated approximately $202 million of aggregate net benefit in Q1 2024, compared with $124 million in Q1 2023. The 2024 amount included approximately $39 million from Nevada’s state-directed payment program.

Liquidity, debt and capital allocation

Cash and cash equivalents were $112 million at March 31, 2024, compared with $119 million at December 31, 2023. Cash, cash equivalents and restricted cash totaled $207 million.
Carrying value of debt was approximately $4.9 billion; fair value was approximately $4.6 billion. Debt represented approximately 44% of total capitalization.
Debt included $2.23 billion outstanding under the tranche A term loan, $463 million of revolving borrowings and $2.0 billion of senior secured notes.
The $1.2 billion revolving facility had $733 million of available borrowing capacity, net of outstanding borrowings and letters of credit. The principal credit facilities mature in 2026.
UHS repaid $64 million of debt, repurchased $142 million of common stock and paid $14 million of dividends during the quarter.
Capital expenditures are expected to total approximately $850 million to $1.0 billion for full-year 2024; UHS expects to fund capital needs and acquisitions through operating cash flow and available financing.
Management stated that operating cash flow, cash, available commitments and capital-market access should provide sufficient resources for the next twelve months. The company was in compliance with its debt covenants at March 31, 2024.

Material changes, outlook and unusual items

Revenue and profitability improved materially year over year, with operating margin expanding by 210 basis points and diluted EPS increasing 68%.
Q1 2024 included approximately $40 million of Nevada state-directed payment revenue and approximately $7 million related to Texas HARP; these programs require regulatory approvals and may be subject to reconciliation or modification.
UHS estimates approximately $158 million of 2024 net reimbursements from both components of the Nevada state-directed payment program, subject to annual CMS approval and utilization-based reconciliation.
UHS expects 2024 net reimbursements of approximately $28 million from HARP. Management also identified potential 2024 QIF revenue of approximately $33 million, expected primarily in the third and fourth quarters.
The filing does not provide formal consolidated earnings or revenue guidance.
UHS recorded a $7 million increase to professional and general liability reserves in Q1 2024. Total accrued professional and general liability claims were $447 million at March 31, 2024.
On March 28, 2024, a jury returned a $60 million compensatory and $475 million punitive damages verdict against Pavilion Behavioral Health System, an indirect subsidiary. UHS intends to challenge the verdict; ultimate exposure is uncertain. Approximately $221 million of commercial insurance coverage remained for the 2020 policy year before considering this matter.
UHS is committed to developing and operating an acute care hospital and related facilities in Washington, D.C. Total projected construction cost is approximately $439 million, funded by the District; approximately $229 million had been incurred by March 31, 2024, and completion is expected in 2025.
Key ongoing risks include labor and physician cost inflation, interest rates, reimbursement reductions, Medicaid supplemental-payment changes, regulatory compliance, litigation, cybersecurity, payer collection risk and foreign-currency exposure.

Important facts for investors to verify

Whether the Pavilion verdict is reduced, overturned, settled or upheld, and the resulting insurance, collateral and cash-flow impact.
The durability and regulatory approval of Nevada, Texas and other Medicaid supplemental-payment programs, including the effect of CMS’s April 2024 managed-care rule.
Whether the $850 million to $1.0 billion 2024 capital expenditure plan remains achievable without materially increasing debt.
Acute care volume and occupancy trends, behavioral health admissions, length of stay and revenue-per-case growth.
Future labor, physician, supplies and interest costs, particularly as variable-rate debt reprices.
Upcoming 2026 maturities, refinancing requirements and continued compliance with leverage covenants.
Potential reductions in Medicaid DSH payments beginning in 2025 and the financial effect of Medicare and Medicaid reimbursement changes.
UHS’s $422.9 million remaining share-repurchase authorization and whether additional repurchases compete with debt reduction or capital investment.